Nigella Sativa as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia
Status:
RECRUITING
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
Nigella sativa is the world's oldest immunomodulator. The main active component in Nigella sativa is thymoquinone. Research shows thymoquinone has antioxidant, anti-inflammatory, and antimicrobial effects. Based on these observations on the pharmacological activities of Nigella sativa, the potential therapeutic efficacy of N. Sativa was proposed in CAP.